We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tocilizumab, recurso terapéutico de vanguardia contra la infección por SARS-CoV-2: una revisión exploratoria.
- Authors
Tuta-Quintero, Eduardo; Mora-Karam, Claudia; Camacho-Osorio, Julia; Rhenals-Acuña, Santiago; Arrieta-Acuña, Francisco; Pérez-Mantilla, Daniela; Alvarado, Nicolás Cristiano; Pimentel, Juan
- Abstract
OBJECTIVE: To explore the medical evidence published until April 20, 2022, about the efficacy and safety of tocilizumab in COVID-19 patients. METHODOLOGY: Scoping review that included PubMed and Scopus, searching for clinical trials and observational studies in English and Spanish. Additionally, records of clinical trials from the International Clinical Trials Registry Platform were analyzed. RESULTS: Fifty-four documents were included: retrospective cohort studies (n = 20), randomized clinical trials (n = 16), case control studies (n = 7), non-randomized clinical trials (n = 5) and prospective cohort studies (n = 6), with a total study population of 20,007 patients. There were 15 records of clinical trials of which 10 were registered in the US National Library of Medicine. CONCLUSIONS: Tocilizumab could be effective and safe to treat patients with moderate to critical COVID-19, in conjunction with additional immunomodulators and antivirals. A greater number of randomized clinical trials, however, are needed to explore the efficacy and safety of tocilizumab.
- Publication
Medicina Interna de Mexico, 2023, Vol 39, Issue 1, p66
- ISSN
0186-4866
- Publication type
Article
- DOI
10.24245/mim.v39i1.7847